JP2021520393A5 - - Google Patents

Info

Publication number
JP2021520393A5
JP2021520393A5 JP2020554864A JP2020554864A JP2021520393A5 JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5 JP 2020554864 A JP2020554864 A JP 2020554864A JP 2020554864 A JP2020554864 A JP 2020554864A JP 2021520393 A5 JP2021520393 A5 JP 2021520393A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520393A (ja
JP7437317B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025363 external-priority patent/WO2019195273A1/en
Publication of JP2021520393A publication Critical patent/JP2021520393A/ja
Publication of JP2021520393A5 publication Critical patent/JP2021520393A5/ja
Priority to JP2024018521A priority Critical patent/JP7829605B2/ja
Application granted granted Critical
Publication of JP7437317B2 publication Critical patent/JP7437317B2/ja
Priority to JP2026033506A priority patent/JP2026090576A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554864A 2018-04-02 2019-04-02 コネキシン43抗体およびその使用 Active JP7437317B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024018521A JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651668P 2018-04-02 2018-04-02
US62/651,668 2018-04-02
PCT/US2019/025363 WO2019195273A1 (en) 2018-04-02 2019-04-02 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018521A Division JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2021520393A JP2021520393A (ja) 2021-08-19
JP2021520393A5 true JP2021520393A5 (cg-RX-API-DMAC7.html) 2022-04-11
JP7437317B2 JP7437317B2 (ja) 2024-02-22

Family

ID=68101187

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554864A Active JP7437317B2 (ja) 2018-04-02 2019-04-02 コネキシン43抗体およびその使用
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A Pending JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A Pending JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Country Status (6)

Country Link
US (2) US12227561B2 (cg-RX-API-DMAC7.html)
JP (3) JP7437317B2 (cg-RX-API-DMAC7.html)
CN (2) CN116854816A (cg-RX-API-DMAC7.html)
AU (2) AU2019249427B2 (cg-RX-API-DMAC7.html)
CA (1) CA3095897A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019195273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3131925A1 (en) * 2019-02-28 2020-09-03 Board Of Regents, The University Of Texas System Compositions for treating osteosarcoma and methods of use
CA3156812A1 (en) 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN113307871B (zh) * 2020-02-27 2023-05-02 福州拓新天成生物科技有限公司 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
AU2024276084A1 (en) * 2023-05-24 2025-12-18 Alamab Therapeutics, Inc. Method of treating bone cancers
US12571255B2 (en) 2023-06-02 2026-03-10 Universal Electronics Inc. Systems and method for controlling window treatments

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
WO2009148613A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AU2017224122B2 (en) * 2016-02-26 2024-04-11 The Board Of Regents Of The University Of Texas System Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations

Similar Documents

Publication Publication Date Title
JP2020537644A5 (cg-RX-API-DMAC7.html)
RU2376316C2 (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2023510350A5 (cg-RX-API-DMAC7.html)
JP2020062036A5 (cg-RX-API-DMAC7.html)
JP2020519643A5 (cg-RX-API-DMAC7.html)
JP2017529838A5 (cg-RX-API-DMAC7.html)
JP2017500018A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2019527194A5 (cg-RX-API-DMAC7.html)
JP2019535763A5 (cg-RX-API-DMAC7.html)
JP2022513420A5 (cg-RX-API-DMAC7.html)
JP2011509245A5 (cg-RX-API-DMAC7.html)
JP2017532952A5 (cg-RX-API-DMAC7.html)
JP2014502955A5 (cg-RX-API-DMAC7.html)
JP2008542278A5 (cg-RX-API-DMAC7.html)
JP2017113019A5 (cg-RX-API-DMAC7.html)
JP2010526028A5 (cg-RX-API-DMAC7.html)
JP2019522961A5 (cg-RX-API-DMAC7.html)
JP2013537418A5 (cg-RX-API-DMAC7.html)
JPWO2020059847A5 (cg-RX-API-DMAC7.html)
JP2015503909A5 (cg-RX-API-DMAC7.html)
JP2018529661A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
JP2022528721A5 (cg-RX-API-DMAC7.html)
JP2022515152A5 (cg-RX-API-DMAC7.html)